Next Article in Journal
Bioaccumulation, Biodistribution, Toxicology and Biomonitoring of Organofluorine Compounds in Aquatic Organisms
Next Article in Special Issue
Effects of Normal Synovial Fluid and Interferon Gamma on Chondrogenic Capability and Immunomodulatory Potential Respectively on Equine Mesenchymal Stem Cells
Previous Article in Journal
Genetic Susceptibility to Periodontal Disease in Down Syndrome: A Case-Control Study
Previous Article in Special Issue
Localization and Maintenance of Engrafted Mesenchymal Stem Cells Administered via Renal Artery in Kidneys with Ischemia-Reperfusion Injury
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing

by
Dito Anurogo
1,2,3,
Nova Yuli Prasetyo Budi
1,2,
Mai-Huong Thi Ngo
1,2,
Yen-Hua Huang
1,2,4,5,6,7,8,9,* and
Jeanne Adiwinata Pawitan
10,11,12,*
1
International PhD Program for Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan
2
Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan
3
Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Makassar, Makassar 90221, Indonesia
4
Research Center of Cell Therapy and Regeneration Medicine, Taipei Medical University, Taipei 11031, Taiwan
5
Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan
6
Center for Reproductive Medicine, Taipei Medical University Hospital, Taipei 11031, Taiwan
7
Comprehensive Cancer Center, Taipei Medical University, Taipei 11031, Taiwan
8
Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei 11031, Taiwan
9
PhD Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan
10
Department of Histology, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia
11
Stem Cell Medical Technology Integrated Service Unit, Cipto Mangunkusumo Central Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia
12
Stem Cell and Tissue Engineering Research Center, Indonesia Medical Education and Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2021, 22(12), 6275; https://doi.org/10.3390/ijms22126275
Submission received: 19 May 2021 / Revised: 6 June 2021 / Accepted: 7 June 2021 / Published: 10 June 2021
(This article belongs to the Special Issue Stem Cells—from Bench to Bedside 2021)

Abstract

Hereditary anemia has various manifestations, such as sickle cell disease (SCD), Fanconi anemia, glucose-6-phosphate dehydrogenase deficiency (G6PDD), and thalassemia. The available management strategies for these disorders are still unsatisfactory and do not eliminate the main causes. As genetic aberrations are the main causes of all forms of hereditary anemia, the optimal approach involves repairing the defective gene, possibly through the transplantation of normal hematopoietic stem cells (HSCs) from a normal matching donor or through gene therapy approaches (either in vivo or ex vivo) to correct the patient’s HSCs. To clearly illustrate the importance of cell and gene therapy in hereditary anemia, this paper provides a review of the genetic aberration, epidemiology, clinical features, current management, and cell and gene therapy endeavors related to SCD, thalassemia, Fanconi anemia, and G6PDD. Moreover, we expound the future research direction of HSC derivation from induced pluripotent stem cells (iPSCs), strategies to edit HSCs, gene therapy risk mitigation, and their clinical perspectives. In conclusion, gene-corrected hematopoietic stem cell transplantation has promising outcomes for SCD, Fanconi anemia, and thalassemia, and it may overcome the limitation of the source of allogenic bone marrow transplantation.
Keywords: cell therapy; gene therapy; anemia; hematopoietic stem cells; gene editing cell therapy; gene therapy; anemia; hematopoietic stem cells; gene editing

Share and Cite

MDPI and ACS Style

Anurogo, D.; Yuli Prasetyo Budi, N.; Thi Ngo, M.-H.; Huang, Y.-H.; Pawitan, J.A. Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing. Int. J. Mol. Sci. 2021, 22, 6275. https://doi.org/10.3390/ijms22126275

AMA Style

Anurogo D, Yuli Prasetyo Budi N, Thi Ngo M-H, Huang Y-H, Pawitan JA. Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing. International Journal of Molecular Sciences. 2021; 22(12):6275. https://doi.org/10.3390/ijms22126275

Chicago/Turabian Style

Anurogo, Dito, Nova Yuli Prasetyo Budi, Mai-Huong Thi Ngo, Yen-Hua Huang, and Jeanne Adiwinata Pawitan. 2021. "Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing" International Journal of Molecular Sciences 22, no. 12: 6275. https://doi.org/10.3390/ijms22126275

APA Style

Anurogo, D., Yuli Prasetyo Budi, N., Thi Ngo, M.-H., Huang, Y.-H., & Pawitan, J. A. (2021). Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing. International Journal of Molecular Sciences, 22(12), 6275. https://doi.org/10.3390/ijms22126275

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop